InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,986.40
(
0.30%
)
Dow Jones
41,393.78
(
0.72%
)
Brent Oil
71.83
(
0.00%
)
Bitcoin
59,955.43
(
-1.03%
)
Post# of 253120
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120432
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 92084

Thursday, 03/11/2010 7:27:31 PM

Thursday, March 11, 2010 7:27:31 PM

Post# of 253120
AGN reacquires Botox cosmeceutical rights in Japan/China from GSK:

http://sec.gov/Archives/edgar/data/850693/000119312510053567/d8k.htm

GSK retains the Botox rights in these countries for medical indications. It never made sense to me that GSK, a company with zero presence in cosmeceuticals, was marketing Botox for cosmetic indications.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up